BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

During the third quarter of 2024, international equities posted strong results: the MSCI ACWI ex USA appreciated 8.1%, ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

TORONTO — Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

While uncertainty often casts a shadow on the Street, U.S. investors welcomed the presidential and congressional election results with a late-night surge that carried into this morning. The Dow Jones ...